Pewnie dla niektórych żadne to pocieszenie, bo się ju dośc naczekali, ale wygląda, że jednak jestesmy blisko rozpoczęcia sprzedaży. Takiej na serio
Last month, we announced the completion of the first economic study of  CompuFlo for use within labor and delivery, which validated the cost  savings of the system versus the traditional loss of resistance  technique. As I mentioned on our last call, by way of example from this  study, if a hospital has 12,000 births per year it would be reasonable  to assume that institution would save over $6 million per year using our  product exclusively. There is no question the economics favor our  product versus the prior art, which, as you know, was invented in the  1800s, using a technique developed in 1921. This is the first major  study to clearly validate the course benefits of the CompuFlo Epidural  System and was the final phase in advancing our commercial rollout.  Having completed obtaining support from key opinion leaders as well as  receiving patents and regulatory approval in the United States and many  other countries, we are now poised to begin our commercial rollout.
https://finance.yahoo.com/news/edited-transcript-mlss-earnings-conference-184635042.html